The termination does not impact Medtronic’s fiscal year 2024 adjusted earnings per share guidance range that the company provided on November 21, 2023. Medtronic continues to advance its automated insulin dosing product pipeline, including a differentiated patch pump.
Related Posts
Fintech Wealthfront valued at $2.63 billion in Nasdaq debut
Dec 12 (Reuters) – Wealthfront’s shares opened flat in their Nasdaq debut on Friday, valuing the automated digital wealth management…
Trump pulls 30 envoys in ‘America First’ push, critics say it weakens US leadership
By Simon Lewis and Humeyra Pamuk WASHINGTON, Dec 22 (Reuters) – The Trump administration is recalling nearly 30 ambassadors and…
Swiss bank UBS closer to getting national bank charter for US franchise
Jan 15 (Reuters) – Swiss bank UBS is a step closer to getting a national bank charter for its U.S.…